tak-448

Small moleculeexperimental

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Nov 1, 2010 (NCT01132404)

Timeline

2010s

Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Jan 1, 2015
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Metastin receptorAGONIST
KISS1R agonist
- KiSS-1 receptor (KISS1R) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O

Mol. weight: 1225.38 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL3924151 ↗

Also known as

ac-(d-tyr46,hyp47,thr49,azagly51,arg(me)53,trp54)metastin (46-54)
metastin (46-54), acetyl-tyr(46)-hyp(47)-thr(49)-azagly(51)-arg(me)(53)-trp(54)-
metastin (46-54), acetyl-tyrosyl(46)-hydroxypropyl(47)-threonyl(49)-azaglycyl(51)-methylarginyl(53)-tryptophyl(54)-
tak-448
tak-448
tak-448
tak-448

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02381288	Phase 2	Sep 10, 2015	Takeda
NCT02369796	Phase 2	Feb 1, 2015	Takeda
NCT01132404	Phase 1/Phase 2 (Phase 2)	Nov 1, 2010	Millennium Pharmaceuticals

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Takeda	For profit	2	2	1	2015
Millennium Pharmaceuticals	For profit	1	1	1	2010

2 organizations

Page 1 / 1